Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Rising High: Exclusive talk with Canadian licensed producer Lotus Ventures » 11:38
06/24/21
06/24
11:38
06/24/21
11:38
LTTSF

Lotus Ventures

/

+

, CBWTF

Auxly Cannabis

/

+

, ACB

Aurora Cannabis

$9.28 /

+0.265 (+2.94%)

, CVSI

CV Sciences

/

+

, CGC

Canopy Growth

$24.39 /

+0.82 (+3.48%)

, CRON

Cronos Group

$8.91 /

+0.27 (+3.13%)

, CANN

General Cannabis

/

+

, IGC

India Globalization Capital

$1.67 /

+0.2 (+13.65%)

, TLRY

Tilray

$18.21 /

+0.61 (+3.47%)

, TCNNF

Trulieve Cannabis

$38.16 /

+2.0109 (+5.56%)

, ZYNE

Zynerba

$5.66 /

+0.09 (+1.62%)

, GDNSF

Goodness Growth

$2.02 /

+0.12 (+6.32%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
$5.66 /

+0.09 (+1.62%)

TLRY Tilray
$18.21 /

+0.61 (+3.47%)

IGC India Globalization Capital
$1.67 /

+0.2 (+13.65%)

CVSI CV Sciences
/

+

CRON Cronos Group
$8.91 /

+0.27 (+3.13%)

CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

CBWTF Auxly Cannabis
/

+

ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

LTTSF Lotus Ventures
/

+

CBWTF Auxly Cannabis
/

+

06/01/21 Desjardins
Auxly Cannabis price target lowered to C$0.60 from C$0.65 at Desjardins
03/10/21 Cantor Fitzgerald
Auxly Cannabis initiated with an Overweight at Cantor Fitzgerald
07/16/20 Desjardins
Auxly Cannabis initiated with a Buy at Desjardins
ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

05/17/21 CIBC
Aurora Cannabis price target lowered to C$8 from C$9 at CIBC
05/14/21
Fly Intel: Top five analyst downgrades
05/14/21 Canaccord
Aurora Cannabis downgraded to Sell from Hold at Canaccord
05/14/21 BMO Capital
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
CVSI CV Sciences
/

+

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/19/21 Piper Sandler
CV Sciences downgraded to Neutral on 'modest' growth at Piper Sandler
03/18/21 Piper Sandler
CV Sciences downgraded to Neutral from Overweight at Piper Sandler
02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

06/03/21 Desjardins
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
06/02/21 CIBC
Canopy Growth price target lowered to C$36 from C$38 at CIBC
06/02/21
Fly Intel: Top five analyst upgrades
06/02/21 MKM Partners
Canopy Growth price target lowered to C$51 from C$55 at MKM Partners
CRON Cronos Group
$8.91 /

+0.27 (+3.13%)

04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/28/21 BofA
BofA reinstates Cronos Group at Underperform with $7.50 price target
04/28/21 BofA
Cronos Group reinitiated with an Underperform at BofA
CANN General Cannabis
/

+

01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
IGC India Globalization Capital
$1.67 /

+0.2 (+13.65%)

TLRY Tilray
$18.21 /

+0.61 (+3.47%)

06/23/21 Alliance Global Partners
Tilray price target lowered to $18 from $32 at Alliance Global Partners
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
TCNNF Trulieve Cannabis
$38.16 /

+2.0109 (+5.56%)

05/12/21 Canaccord
Trulieve Cannabis price target raised to C$97 from C$90 at Canaccord
05/12/21 Stifel
Trulieve Cannabis price target raised to C$132 from C$118 at Stifel
05/10/21 Roth Capital
Trulieve deal for Harvest Health 'strategic vs. synergistic,' says Roth Capital
04/15/21 Cowen
Trulieve Cannabis initiated with an Outperform at Cowen
ZYNE Zynerba
$5.66 /

+0.09 (+1.62%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
02/03/21 Ladenburg
Jazz deal for GW 'spotlights' value of Zynerba CBD products, says Ladenburg
GDNSF Goodness Growth
$2.02 /

+0.12 (+6.32%)

ZYNE Zynerba
$5.66 /

+0.09 (+1.62%)

TLRY Tilray
$18.21 /

+0.61 (+3.47%)

CRON Cronos Group
$8.91 /

+0.27 (+3.13%)

CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

CBWTF Auxly Cannabis
/

+

ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

  • 22
    Jan
  • 11
    Nov
CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

CBWTF Auxly Cannabis
/

+

ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

TLRY Tilray
$18.21 /

+0.61 (+3.47%)

LTTSF Lotus Ventures
/

+

CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

CBWTF Auxly Cannabis
/

+

ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

ZYNE Zynerba
$5.66 /

+0.09 (+1.62%)

TLRY Tilray
$18.21 /

+0.61 (+3.47%)

IGC India Globalization Capital
$1.67 /

+0.2 (+13.65%)

CRON Cronos Group
$8.91 /

+0.27 (+3.13%)

CGC Canopy Growth
$24.39 /

+0.82 (+3.48%)

ACB Aurora Cannabis
$9.28 /

+0.265 (+2.94%)

Options
Tilray call volume above normal and directionally bullish » 10:45
06/24/21
06/24
10:45
06/24/21
10:45
TLRY

Tilray

$18.13 /

+0.53 (+3.01%)

Bullish option flow…

Bullish option flow detected in Tilray with 74,699 calls trading, 1.2x expected, and implied vol increasing over 2 points to 91.63%. 6/25 weekly 18.5 calls and 6/25 weekly 20 calls are the most active options, with total volume in those strikes near 20,100 contracts. The Put/Call Ratio is 0.13. Earnings are expected on August 9th.

ShowHide Related Items >><<
TLRY Tilray
$18.13 /

+0.53 (+3.01%)

TLRY Tilray
$18.13 /

+0.53 (+3.01%)

06/23/21 Alliance Global Partners
Tilray price target lowered to $18 from $32 at Alliance Global Partners
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
TLRY Tilray
$18.13 /

+0.53 (+3.01%)

TLRY Tilray
$18.13 /

+0.53 (+3.01%)

TLRY Tilray
$18.13 /

+0.53 (+3.01%)

TLRY Tilray
$18.13 /

+0.53 (+3.01%)

Yesterday
Recommendations
Tilray price target lowered to $18 from $32 at Alliance Global Partners » 08:11
06/23/21
06/23
08:11
06/23/21
08:11
TLRY

Tilray

$17.43 /

+0.07 (+0.40%)

Alliance Global Partners…

Alliance Global Partners analyst Aaron Grey lowered the firm's price target on Tilray to $18 from $32 and keeps a Neutral rating on the shares. The analyst sees the combination with Aphria as beneficial "with each company offering complementary strengths," but he believes Tilray is fairly valued at current share price levels. Grey cites valuation and uncertainty of near-term market share gains in Canada for the Neutral rating.

ShowHide Related Items >><<
TLRY Tilray
$17.43 /

+0.07 (+0.40%)

TLRY Tilray
$17.43 /

+0.07 (+0.40%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
TLRY Tilray
$17.43 /

+0.07 (+0.40%)

TLRY Tilray
$17.43 /

+0.07 (+0.40%)

TLRY Tilray
$17.43 /

+0.07 (+0.40%)

TLRY Tilray
$17.43 /

+0.07 (+0.40%)

Tuesday
Hot Stocks
NIH says cannabis may be associated with suicidality in young adults » 11:29
06/22/21
06/22
11:29
06/22/21
11:29
ACB

Aurora Cannabis

$8.78 /

-0.19 (-2.12%)

, CGC

Canopy Growth

$23.07 /

-0.35 (-1.49%)

, IGC

India Globalization Capital

$1.48 /

-0.01 (-0.67%)

, CANN

General Cannabis

/

+

, ZYNE

Zynerba

$5.41 /

-0.1 (-1.81%)

, CRON

Cronos Group

$8.39 /

-0.18 (-2.10%)

, TLRY

Tilray

$17.03 /

-0.33 (-1.90%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, TCNNF

Trulieve Cannabis

$37.00 /

+1.08 (+3.01%)

An analysis of survey…

An analysis of survey data from more than 280,000 young adults ages 18-35 showed that cannabis use was associated with increased risks of thoughts of suicide, suicide plan, and suicide attempt. These associations remained regardless of whether someone was also experiencing depression, and the risks were greater for women than for men. For their analysis, NIDA researchers examined data from the 2008-2019 National Surveys on Drug Use and Health. NSDUH, which is conducted annually by the Substance Abuse and Mental Health Services Administration, collects nationally representative data among the U.S. civilian, noninstitutionalized population age 12 or older on cannabis use and use disorder, depression, suicidality, and other behavioral health indicators. In addition to determining the associations between these factors, the researchers examined whether the associations varied by gender. They examined data from 281,650 young adults ages 18 to 35 years - the age range when most substance use and mood disorders emerge-with an almost even number of women and men. The researchers compared four levels of past-year cannabis use: no cannabis use; nondaily cannabis use; daily cannabis use, which was defined as use on at least 300 days per year; and presence of cannabis use disorder, which was assessed in the survey and involves meeting specific criteria for a pattern of continued cannabis use despite negative consequences. To determine the presence of depression, they assessed the prevalence of major depressive episodes based on specific diagnostic criteria measured through the survey. To identify suicidality trends, the investigators separately assessed the trends in the prevalence of past-year suicidal ideation, plan, and attempt as reported in the 2008-2019 NSDUH surveys. The results of the study indicated that even people who used cannabis nondaily, fewer than 300 days a year, were more likely to have suicidal ideation and to plan or attempt suicide than those who did not use the drug at all. These associations remained regardless of whether someone was also experiencing depression. Among people without a major depressive episode, about 3% of those who did not use cannabis had suicidal ideation, compared with about 7% of those with nondaily cannabis use, about 9% of those with daily cannabis use, and 14% of those with a cannabis use disorder. Among people with depression, 35% of people who did not use cannabis had suicidal ideation, compared to 44% of those with nondaily cannabis use, 53% of those who used cannabis daily, and 50% of those who had a cannabis use disorder. Similar trends existed for the associations between different levels of cannabis use and suicide plan or attempt. Moreover, the researchers found that women who used cannabis at any level were more likely to have suicidal ideation or report a suicide plan or attempt than men with the same levels of cannabis use. For example, among individuals without major depressive episode, the prevalence of suicidal ideation for those with vs. without a cannabis use disorder was 13.9% vs. 3.5% among women and 9.9% vs. 3.0% among men. Among individuals with both cannabis use disorder and major depressive episode, the prevalence of past-year suicide plan was 52% higher for women than men. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CTST), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE).

ShowHide Related Items >><<
ZYNE Zynerba
$5.41 /

-0.1 (-1.81%)

TLRY Tilray
$17.03 /

-0.33 (-1.90%)

TCNNF Trulieve Cannabis
$37.00 /

+1.08 (+3.01%)

IGC India Globalization Capital
$1.48 /

-0.01 (-0.67%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$8.39 /

-0.18 (-2.10%)

CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

CANN General Cannabis
/

+

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

05/17/21 CIBC
Aurora Cannabis price target lowered to C$8 from C$9 at CIBC
05/14/21
Fly Intel: Top five analyst downgrades
05/14/21 Canaccord
Aurora Cannabis downgraded to Sell from Hold at Canaccord
05/14/21 BMO Capital
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

06/03/21 Desjardins
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
06/02/21 CIBC
Canopy Growth price target lowered to C$36 from C$38 at CIBC
06/02/21
Fly Intel: Top five analyst upgrades
06/02/21 MKM Partners
Canopy Growth price target lowered to C$51 from C$55 at MKM Partners
IGC India Globalization Capital
$1.48 /

-0.01 (-0.67%)

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
CANN General Cannabis
/

+

ZYNE Zynerba
$5.41 /

-0.1 (-1.81%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
02/03/21 Ladenburg
Jazz deal for GW 'spotlights' value of Zynerba CBD products, says Ladenburg
CRON Cronos Group
$8.39 /

-0.18 (-2.10%)

04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/28/21 BofA
BofA reinstates Cronos Group at Underperform with $7.50 price target
04/28/21 BofA
Cronos Group reinitiated with an Underperform at BofA
TLRY Tilray
$17.03 /

-0.33 (-1.90%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
CVSI CV Sciences
/

+

03/19/21 Piper Sandler
CV Sciences downgraded to Neutral on 'modest' growth at Piper Sandler
03/18/21 Piper Sandler
CV Sciences downgraded to Neutral from Overweight at Piper Sandler
CTST CannTrust
/

+

TCNNF Trulieve Cannabis
$37.00 /

+1.08 (+3.01%)

05/12/21 Canaccord
Trulieve Cannabis price target raised to C$97 from C$90 at Canaccord
05/12/21 Stifel
Trulieve Cannabis price target raised to C$132 from C$118 at Stifel
05/10/21 Roth Capital
Trulieve deal for Harvest Health 'strategic vs. synergistic,' says Roth Capital
04/15/21 Cowen
Trulieve Cannabis initiated with an Outperform at Cowen
ZYNE Zynerba
$5.41 /

-0.1 (-1.81%)

TLRY Tilray
$17.03 /

-0.33 (-1.90%)

CRON Cronos Group
$8.39 /

-0.18 (-2.10%)

CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

  • 22
    Jan
  • 11
    Nov
CTST CannTrust
/

+

CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

TLRY Tilray
$17.03 /

-0.33 (-1.90%)

CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

ZYNE Zynerba
$5.41 /

-0.1 (-1.81%)

TLRY Tilray
$17.03 /

-0.33 (-1.90%)

IGC India Globalization Capital
$1.48 /

-0.01 (-0.67%)

CRON Cronos Group
$8.39 /

-0.18 (-2.10%)

CGC Canopy Growth
$23.07 /

-0.35 (-1.49%)

ACB Aurora Cannabis
$8.78 /

-0.19 (-2.12%)

Over a week ago
Hot Stocks
Connecticut Governor 'looks forward' to signing adult-use cannabis bill » 12:32
06/17/21
06/17
12:32
06/17/21
12:32
ACB

Aurora Cannabis

$9.12 /

-0.14 (-1.51%)

, CGC

Canopy Growth

$23.81 /

-0.3 (-1.24%)

, IGC

India Globalization Capital

$1.55 /

-0.035 (-2.21%)

, CANN

General Cannabis

/

+

, ZYNE

Zynerba

$5.51 /

-0.1 (-1.78%)

, CRON

Cronos Group

$8.53 /

-0.085 (-0.99%)

, TLRY

Tilray

$17.65 /

-0.48 (-2.65%)

, CVSI

CV Sciences

/

+

, CNTTF

CannTrust Holdings

/

+

, TCNNF

Trulieve Cannabis

$35.70 /

+0.1 (+0.28%)

Governor Ned Lamont…

Governor Ned Lamont released a statement regarding final approval in the Connecticut General Assembly of legislation legalizing adult-use cannabis in Connecticut, in which he stated in part: "It's fitting that the bill legalizing the adult use of cannabis and addressing the injustices caused by the war of drugs received final passage today, on the 50-year anniversary of President Nixon declaring the war... The states surrounding us already, or soon will, have legal adult-use markets. By allowing adults to possess cannabis, regulating its sale and content, training police officers in the latest techniques of detecting and preventing impaired driving, and expunging the criminal records of people with certain cannabis crimes, we're not only effectively modernizing our laws and addressing inequities, we're keeping Connecticut economically competitive with our neighboring states. Connecticut residents will benefit from the portion of cannabis revenues that will be dedicated to prevention and recovery services. This measure is comprehensive, protects our children and the most vulnerable in our communities, and will be viewed as a national model for regulating the adult-use cannabis marketplace. I look forward to signing the bill and moving beyond this terrible period of incarceration and injustice." Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE).

ShowHide Related Items >><<
ZYNE Zynerba
$5.51 /

-0.1 (-1.78%)

TLRY Tilray
$17.65 /

-0.48 (-2.65%)

TCNNF Trulieve Cannabis
$35.70 /

+0.1 (+0.28%)

IGC India Globalization Capital
$1.55 /

-0.035 (-2.21%)

CVSI CV Sciences
/

+

CRON Cronos Group
$8.53 /

-0.085 (-0.99%)

CNTTF CannTrust Holdings
/

+

CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

CANN General Cannabis
/

+

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

05/17/21 CIBC
Aurora Cannabis price target lowered to C$8 from C$9 at CIBC
05/14/21
Fly Intel: Top five analyst downgrades
05/14/21 Canaccord
Aurora Cannabis downgraded to Sell from Hold at Canaccord
05/14/21 BMO Capital
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

06/03/21 Desjardins
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
06/02/21 CIBC
Canopy Growth price target lowered to C$36 from C$38 at CIBC
06/02/21
Fly Intel: Top five analyst upgrades
06/02/21 MKM Partners
Canopy Growth price target lowered to C$51 from C$55 at MKM Partners
IGC India Globalization Capital
$1.55 /

-0.035 (-2.21%)

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
CANN General Cannabis
/

+

ZYNE Zynerba
$5.51 /

-0.1 (-1.78%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
02/03/21 Ladenburg
Jazz deal for GW 'spotlights' value of Zynerba CBD products, says Ladenburg
CRON Cronos Group
$8.53 /

-0.085 (-0.99%)

04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/28/21 BofA
BofA reinstates Cronos Group at Underperform with $7.50 price target
04/28/21 BofA
Cronos Group reinitiated with an Underperform at BofA
TLRY Tilray
$17.65 /

-0.48 (-2.65%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
CVSI CV Sciences
/

+

03/19/21 Piper Sandler
CV Sciences downgraded to Neutral on 'modest' growth at Piper Sandler
03/18/21 Piper Sandler
CV Sciences downgraded to Neutral from Overweight at Piper Sandler
CNTTF CannTrust Holdings
/

+

TCNNF Trulieve Cannabis
$35.70 /

+0.1 (+0.28%)

05/12/21 Canaccord
Trulieve Cannabis price target raised to C$97 from C$90 at Canaccord
05/12/21 Stifel
Trulieve Cannabis price target raised to C$132 from C$118 at Stifel
05/10/21 Roth Capital
Trulieve deal for Harvest Health 'strategic vs. synergistic,' says Roth Capital
04/15/21 Cowen
Trulieve Cannabis initiated with an Outperform at Cowen
ZYNE Zynerba
$5.51 /

-0.1 (-1.78%)

TLRY Tilray
$17.65 /

-0.48 (-2.65%)

CRON Cronos Group
$8.53 /

-0.085 (-0.99%)

CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

  • 22
    Jan
  • 11
    Nov
CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

TLRY Tilray
$17.65 /

-0.48 (-2.65%)

CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

ZYNE Zynerba
$5.51 /

-0.1 (-1.78%)

TLRY Tilray
$17.65 /

-0.48 (-2.65%)

IGC India Globalization Capital
$1.55 /

-0.035 (-2.21%)

CRON Cronos Group
$8.53 /

-0.085 (-0.99%)

CGC Canopy Growth
$23.81 /

-0.3 (-1.24%)

ACB Aurora Cannabis
$9.12 /

-0.14 (-1.51%)

On The Fly
Rising High: Analyst more cautious on Tilray despite legalization bill » 12:08
06/17/21
06/17
12:08
06/17/21
12:08
CGC

Canopy Growth

$23.98 /

-0.13 (-0.54%)

, SPRWF

Supreme Cannabis

/

+

, TCNNF

Trulieve Cannabis

$35.70 /

+0.1 (+0.28%)

, IGC

India Globalization Capital

$1.57 /

-0.015 (-0.95%)

, CANN

General Cannabis

/

+

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, ACB

Aurora Cannabis

$9.19 /

-0.07 (-0.76%)

, KERN

Akerna

$4.44 /

+0.12 (+2.78%)

, ZYNE

Zynerba

$5.57 /

-0.04 (-0.71%)

, CRON

Cronos Group

$8.62 /

+0.005 (+0.06%)

, CLVR

Clever Leaves

$10.74 /

-0.11 (-1.01%)

, HEXO

Hexo

$5.79 /

-0.095 (-1.61%)

, TLRY

Tilray

$17.94 /

-0.19 (-1.05%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$5.57 /

-0.04 (-0.71%)

TLRY Tilray
$17.94 /

-0.19 (-1.05%)

TCNNF Trulieve Cannabis
$35.70 /

+0.1 (+0.28%)

SPRWF Supreme Cannabis
/

+

KERN Akerna
$4.44 /

+0.12 (+2.78%)

IGC India Globalization Capital
$1.57 /

-0.015 (-0.95%)

HEXO Hexo
$5.79 /

-0.095 (-1.61%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$8.62 /

+0.005 (+0.06%)

CLVR Clever Leaves
$10.74 /

-0.11 (-1.01%)

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

CANN General Cannabis
/

+

ACB Aurora Cannabis
$9.19 /

-0.07 (-0.76%)

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

06/03/21 Desjardins
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
06/02/21 CIBC
Canopy Growth price target lowered to C$36 from C$38 at CIBC
06/02/21
Fly Intel: Top five analyst upgrades
06/02/21 MKM Partners
Canopy Growth price target lowered to C$51 from C$55 at MKM Partners
SPRWF Supreme Cannabis
/

+

04/09/21 Stifel
Supreme Cannabis downgraded to Sell from Buy at Stifel
04/09/21 Stifel
Supreme Cannabis downgraded to Sell from Buy at Stifel
03/10/21 BMO Capital
Supreme Cannabis upgraded to Outperform from Market Perform at BMO Capital
02/16/21 Stifel
Supreme Cannabis price target raised to C$0.55 from C$0.20 at Stifel
TCNNF Trulieve Cannabis
$35.70 /

+0.1 (+0.28%)

05/12/21 Canaccord
Trulieve Cannabis price target raised to C$97 from C$90 at Canaccord
05/12/21 Stifel
Trulieve Cannabis price target raised to C$132 from C$118 at Stifel
05/10/21 Roth Capital
Trulieve deal for Harvest Health 'strategic vs. synergistic,' says Roth Capital
04/15/21 Cowen
Trulieve Cannabis initiated with an Outperform at Cowen
IGC India Globalization Capital
$1.57 /

-0.015 (-0.95%)

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
CANN General Cannabis
/

+

CVSI CV Sciences
/

+

03/19/21 Piper Sandler
CV Sciences downgraded to Neutral on 'modest' growth at Piper Sandler
03/18/21 Piper Sandler
CV Sciences downgraded to Neutral from Overweight at Piper Sandler
CTST CannTrust
/

+

ACB Aurora Cannabis
$9.19 /

-0.07 (-0.76%)

05/17/21 CIBC
Aurora Cannabis price target lowered to C$8 from C$9 at CIBC
05/14/21
Fly Intel: Top five analyst downgrades
05/14/21 Canaccord
Aurora Cannabis downgraded to Sell from Hold at Canaccord
05/14/21 BMO Capital
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
KERN Akerna
$4.44 /

+0.12 (+2.78%)

02/05/21 Alliance Global Partners
Akerna price target raised to $10.50 from $8 at Alliance Global Partners
11/12/20 Alliance Global Partners
Akerna price target lowered to $8 from $10 at Alliance Global Partners
11/04/20 Alliance Global Partners
Five states legalize cannabis, bullish for Akerna, says Alliance Global Partners
09/24/20 Alliance Global Partners
Akerna post-earnings selloff overdone, says Alliance Global Partners
ZYNE Zynerba
$5.57 /

-0.04 (-0.71%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
02/03/21 Ladenburg
Jazz deal for GW 'spotlights' value of Zynerba CBD products, says Ladenburg
CRON Cronos Group
$8.62 /

+0.005 (+0.06%)

04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/28/21 BofA
BofA reinstates Cronos Group at Underperform with $7.50 price target
04/28/21 BofA
Cronos Group reinitiated with an Underperform at BofA
CLVR Clever Leaves
$10.74 /

-0.11 (-1.01%)

HEXO Hexo
$5.79 /

-0.095 (-1.61%)

06/16/21 Desjardins
Hexo price target lowered to C$7.50 from C$8 at Desjardins
06/15/21 Canaccord
Hexo price target lowered to C$7 from C$9 at Canaccord
06/15/21 CIBC
Hexo price target lowered to C$10 from C$13.50 at CIBC
05/28/21 Stifel
Hexo has risk of facing competing bidder for Redecan, says Stifel
TLRY Tilray
$17.94 /

-0.19 (-1.05%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
ZYNE Zynerba
$5.57 /

-0.04 (-0.71%)

TLRY Tilray
$17.94 /

-0.19 (-1.05%)

CRON Cronos Group
$8.62 /

+0.005 (+0.06%)

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

ACB Aurora Cannabis
$9.19 /

-0.07 (-0.76%)

  • 22
    Jan
  • 11
    Nov
SPRWF Supreme Cannabis
/

+

IGC India Globalization Capital
$1.57 /

-0.015 (-0.95%)

CTST CannTrust
/

+

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

TLRY Tilray
$17.94 /

-0.19 (-1.05%)

TCNNF Trulieve Cannabis
$35.70 /

+0.1 (+0.28%)

SPRWF Supreme Cannabis
/

+

HEXO Hexo
$5.79 /

-0.095 (-1.61%)

CLVR Clever Leaves
$10.74 /

-0.11 (-1.01%)

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

ZYNE Zynerba
$5.57 /

-0.04 (-0.71%)

TLRY Tilray
$17.94 /

-0.19 (-1.05%)

KERN Akerna
$4.44 /

+0.12 (+2.78%)

IGC India Globalization Capital
$1.57 /

-0.015 (-0.95%)

HEXO Hexo
$5.79 /

-0.095 (-1.61%)

CRON Cronos Group
$8.62 /

+0.005 (+0.06%)

CLVR Clever Leaves
$10.74 /

-0.11 (-1.01%)

CGC Canopy Growth
$23.98 /

-0.13 (-0.54%)

ACB Aurora Cannabis
$9.19 /

-0.07 (-0.76%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:54
06/11/21
06/11
09:54
06/11/21
09:54
VRTX

Vertex Pharmaceuticals

$198.19 /

-18.76 (-8.65%)

, TLRY

Tilray

$19.80 /

-0.26 (-1.30%)

, LOGI

Logitech

$128.48 /

-4.145 (-3.13%)

, OCGN

Ocugen

$6.71 /

+ (+0.00%)

, QUMU

Qumu

$3.88 /

-0.86 (-18.14%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Vertex Pharmaceuticals (VRTX) downgraded to Neutral from Outperform at Daiwa with analyst Narumi Nakagiri citing the announcement that VX-864 will not advance into late-stage development. 2. Tilray (TLRY) downgraded to Neutral from Outperformer at CIBC with analyst John Zamparo saying the upcoming release of Senator Schumer's cannabis federal legalization bill will likely create a positive catalyst, but "it's uncertain to lead to meaningful change this year." 3. Logitech (LOGI) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Katy Huberty saying the stock has risen over 250% since the start of the pandemic, even as its earnings revisions moderate and proxies suggest softer demand. 4. Ocugen (OCGN) downgraded to Neutral from Buy at Roth Capital with analyst Zegbeh Jallah saying he wrongly expected the FDA to review the EUA application, so the news is "disappointing." 5. Qumu (QUMU) downgraded to Hold from Buy at Craig-Hallum with analyst Jeff Van Rhee believing the new "volume and velocity" sales motion is missing the mark and that bookings are lagging the levels needed to achieve the firm's prior estimates of 9% growth in 2021. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

TLRY Tilray
$19.80 /

-0.26 (-1.30%)

QUMU Qumu
$3.88 /

-0.86 (-18.14%)

OCGN Ocugen
$6.71 /

+ (+0.00%)

LOGI Logitech
$128.48 /

-4.145 (-3.13%)

VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
06/11/21 Goldman Sachs
Vertex trading below cystic fibrosis franchise value, says Goldman Sachs
06/11/21 Morgan Stanley
Vertex Pharmaceuticals price target lowered to $205 from $254 at Morgan Stanley
TLRY Tilray
$19.80 /

-0.26 (-1.30%)

06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
06/02/21 Cantor Fitzgerald
Cantor upgrades Tilray to Overweight following Aphria merger
LOGI Logitech
$128.48 /

-4.145 (-3.13%)

06/10/21 Morgan Stanley
Logitech downgraded to Equal Weight from Overweight at Morgan Stanley
05/03/21 Loop Capital
Logitech price target raised to $130 from $120 at Loop Capital
03/02/21 Credit Suisse
Logitech price target raised to CHF 121 from CHF 116 at Credit Suisse
03/02/21 DA Davidson
Logitech price target raised to $135 from $119 at DA Davidson
OCGN Ocugen
$6.71 /

+ (+0.00%)

06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
06/10/21 Roth Capital
Ocugen downgraded to Neutral from Buy at Roth Capital
06/10/21 Chardan
Ocugen price target lowered to $4.50 from $8 at Chardan
06/03/21 Roth Capital
Ocugen gaining Covaxin in Canada rights 'smart move,' says Roth Capital
QUMU Qumu
$3.88 /

-0.86 (-18.14%)

06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
02/12/21 Lake Street
Synacor downgraded to Hold from Buy at Lake Street
02/08/21
Fly Intel: Top five analyst initiations
VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

TLRY Tilray
$19.80 /

-0.26 (-1.30%)

QUMU Qumu
$3.88 /

-0.86 (-18.14%)

OCGN Ocugen
$6.71 /

+ (+0.00%)

LOGI Logitech
$128.48 /

-4.145 (-3.13%)

  • 27
    Jan
VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

TLRY Tilray
$19.80 /

-0.26 (-1.30%)

OCGN Ocugen
$6.71 /

+ (+0.00%)

VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

TLRY Tilray
$19.80 /

-0.26 (-1.30%)

QUMU Qumu
$3.88 /

-0.86 (-18.14%)

OCGN Ocugen
$6.71 /

+ (+0.00%)

LOGI Logitech
$128.48 /

-4.145 (-3.13%)

VRTX Vertex Pharmaceuticals
$198.19 /

-18.76 (-8.65%)

TLRY Tilray
$19.80 /

-0.26 (-1.30%)

OCGN Ocugen
$6.71 /

+ (+0.00%)

LOGI Logitech
$128.48 /

-4.145 (-3.13%)

Downgrade
Tilray downgraded to Neutral after 33% rally at CIBC » 06:39
06/11/21
06/11
06:39
06/11/21
06:39
TLRY

Tilray

$20.06 /

-1.355 (-6.33%)

CIBC analyst John Zamparo…

CIBC analyst John Zamparo last night downgraded Tilray to Neutral from Outperformer with an unchanged price target of $25. The upcoming release of Senator Schumer's cannabis federal legalization bill will likely create a positive catalyst, but "it's uncertain to lead to meaningful change this year," Zamparo tells investors in a research note. Tilray shares are up 33% since the Aphria merger, and the valuation "leaves little upside from here," says the analyst.

ShowHide Related Items >><<
TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
06/03/21
Fly Intel: Top five analyst upgrades
06/02/21 Cantor Fitzgerald
Cantor upgrades Tilray to Overweight following Aphria merger
06/02/21 Cantor Fitzgerald
Tilray upgraded to Overweight from Neutral at Cantor Fitzgerald
TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

Downgrade
Tilray downgraded to Neutral from Outperformer at CIBC » 18:26
06/10/21
06/10
18:26
06/10/21
18:26
TLRY

Tilray

$20.06 /

-1.355 (-6.33%)

CIBC analyst John Zamparo…

CIBC analyst John Zamparo downgraded Tilray to Neutral from Outperformer with a $25 price target.

ShowHide Related Items >><<
TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

06/03/21
Fly Intel: Top five analyst upgrades
06/02/21 Cantor Fitzgerald
Cantor upgrades Tilray to Overweight following Aphria merger
06/02/21 Cantor Fitzgerald
Tilray upgraded to Overweight from Neutral at Cantor Fitzgerald
05/11/21 Cowen
Tilray resumed with Outperform at Cowen
TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

TLRY Tilray
$20.06 /

-1.355 (-6.33%)

On The Fly
Rising High: An exclusive talk with medical cannabis operator Redbird » 11:58
06/10/21
06/10
11:58
06/10/21
11:58
ACB

Aurora Cannabis

$9.84 /

-0.385 (-3.77%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$25.30 /

-0.41 (-1.59%)

, CRON

Cronos Group

$8.73 /

-0.315 (-3.48%)

, CANN

General Cannabis

/

+

, IGC

India Globalization Capital

$1.52 /

-0.04 (-2.56%)

, TLRY

Tilray

$20.08 /

-1.33 (-6.21%)

, TCNNF

Trulieve Cannabis

$38.05 /

-0.15 (-0.39%)

, ZYNE

Zynerba

$5.46 /

-0.1 (-1.80%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
$5.46 /

-0.1 (-1.80%)

TLRY Tilray
$20.08 /

-1.33 (-6.21%)

TCNNF Trulieve Cannabis
$38.05 /

-0.15 (-0.39%)

IGC India Globalization Capital
$1.52 /

-0.04 (-2.56%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$8.73 /

-0.315 (-3.48%)

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

CANN General Cannabis
/

+

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

05/17/21 CIBC
Aurora Cannabis price target lowered to C$8 from C$9 at CIBC
05/14/21
Fly Intel: Top five analyst downgrades
05/14/21 Canaccord
Aurora Cannabis downgraded to Sell from Hold at Canaccord
05/14/21 BMO Capital
Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital
CVSI CV Sciences
/

+

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/19/21 Piper Sandler
CV Sciences downgraded to Neutral on 'modest' growth at Piper Sandler
03/18/21 Piper Sandler
CV Sciences downgraded to Neutral from Overweight at Piper Sandler
02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
CTST CannTrust
/

+

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

06/03/21 Desjardins
Canopy Growth price target lowered to C$35 from C$55 at Desjardins
06/02/21 CIBC
Canopy Growth price target lowered to C$36 from C$38 at CIBC
06/02/21
Fly Intel: Top five analyst upgrades
06/02/21 MKM Partners
Canopy Growth price target lowered to C$51 from C$55 at MKM Partners
CRON Cronos Group
$8.73 /

-0.315 (-3.48%)

04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/28/21 BofA
BofA reinstates Cronos Group at Underperform with $7.50 price target
04/28/21 BofA
Cronos Group reinitiated with an Underperform at BofA
CANN General Cannabis
/

+

01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
IGC India Globalization Capital
$1.52 /

-0.04 (-2.56%)

TLRY Tilray
$20.08 /

-1.33 (-6.21%)

06/23/21 Alliance Global Partners
Tilray price target lowered to $18 from $32 at Alliance Global Partners
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 CIBC
Tilray downgraded to Neutral after 33% rally at CIBC
06/10/21 CIBC
Tilray downgraded to Neutral from Outperformer at CIBC
TCNNF Trulieve Cannabis
$38.05 /

-0.15 (-0.39%)

05/12/21 Canaccord
Trulieve Cannabis price target raised to C$97 from C$90 at Canaccord
05/12/21 Stifel
Trulieve Cannabis price target raised to C$132 from C$118 at Stifel
05/10/21 Roth Capital
Trulieve deal for Harvest Health 'strategic vs. synergistic,' says Roth Capital
04/15/21 Cowen
Trulieve Cannabis initiated with an Outperform at Cowen
ZYNE Zynerba
$5.46 /

-0.1 (-1.80%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
02/03/21 Ladenburg
Jazz deal for GW 'spotlights' value of Zynerba CBD products, says Ladenburg
ZYNE Zynerba
$5.46 /

-0.1 (-1.80%)

TLRY Tilray
$20.08 /

-1.33 (-6.21%)

CRON Cronos Group
$8.73 /

-0.315 (-3.48%)

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

  • 22
    Jan
  • 11
    Nov
CTST CannTrust
/

+

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

TLRY Tilray
$20.08 /

-1.33 (-6.21%)

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

ZYNE Zynerba
$5.46 /

-0.1 (-1.80%)

TLRY Tilray
$20.08 /

-1.33 (-6.21%)

IGC India Globalization Capital
$1.52 /

-0.04 (-2.56%)

CRON Cronos Group
$8.73 /

-0.315 (-3.48%)

CGC Canopy Growth
$25.30 /

-0.41 (-1.59%)

ACB Aurora Cannabis
$9.84 /

-0.385 (-3.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.